September 29, 2016 3:53 PM ET


Company Overview of Asterand Bioscience, Inc.

Company Overview

Asterand Bioscience, Inc. develops technology and application solutions that provide researchers the tools to investigate and understand cellular reprogramming worldwide. It provides a set of tools for generating iPS cells, as well as cell lines, media, differentiation, rabbit anti-mouse/human, cytokines/proteins, matrices, reprogramming systems, transfection reagents, small molecules, and antibodies; and iPS cell services, training courses, and video protocols. The company serves reprogramming, self-renewal, and differentiation applications. Asterand Bioscience, Inc. was formerly known as Stemgent, Inc. and changed its name to Asterand Bioscience, Inc. in October 2014. The company was incor...

51 Moulton Street

Cambridge, MA 02138

United States

Founded in 2007





Key Executives for Asterand Bioscience, Inc.

Executive Chairman
Age: 55
Chief Financial Officer
Chief Operating Officer and Executive Vice President
Chief Commercial Officer
Vice President
Compensation as of Fiscal Year 2016.

Asterand Bioscience, Inc. Key Developments

Asterand Bioscience Wins $6.5 Million Contract from National Institutes of Health

Asterand Bioscience announced that is has been awarded a five-year, $6.5 million contract from the National Institutes of Health (NIH) to provide oncology specimens with associated clinical data to the Clinical Proteomic Tumor Analysis Consortium (CPTAC).

Stemgent Inc. Launches its New Stemgent StemRNA - SR Reprogramming Kit

Stemgent Inc. has launched its new Stemgent StemRNA - SR Reprogramming Kit, the first commercially available RNA reprogramming kit applicable to cellular reprogramming of a blood-derived cell type. This non-viral, non-DNA reprogramming kit combines self-replicative RNA (srRNA) and microRNA technology, providing stem cell researchers with a safe, flexible and cost-effective cellular reprogramming method applicable to both human fibroblasts and blood-derived endothelial progenitor cells (EPCs). EPCs are uniquely genetically stable and can be efficiently established from fresh or cryopreserved human peripheral and cord blood. This latest innovation is being unveiled at the 13th Annual Meeting of the International Society for Stem Cell Research (ISSCR), June 24, 2015 - June 27, 2015 in Stockholm, Sweden.

Stemgent, Inc. and Transposagen Biopharmaceuticals Inc. Enters into Partnership Agreement for Development of Genetically Engineered Induced Pluripotent Stem Cells Services for Pharmaceutical, Biotechnology, Academic and Government Organizations

Stemgent, Inc. and Transposagen Biopharmaceuticals Inc. announced that they have entered into a partnership agreement enabling the development of genetically engineered induced pluripotent stem cells (iPSC) services for pharmaceutical, biotechnology, academic and government organizations. The non-exclusive agreement combines Stemgent's industry-recognized expertise in RNA reprogramming with Transposagen's unique genome editing capabilities providing researchers with the convenience of a single point of contact for customer research or disease model systems using patient-specific iPS cells. The newly created service provides customers with a beginning to end solution, starting with Stemgent's expertise in primary cell establishment and iPS cell generation, through genetic manipulation using Transposagen's diverse methods, and ending with a validated cell line that is capable of appropriate differentiation to cardiomyocytes, neurons or hepatocytes.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Asterand Bioscience, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at